Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.69 |
| ▸ | TP53 | P04637 | 3/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12260311 | 1.00 | RXFP1 (0.69) | RXFP1TP53MAPK1KMT2AMEN1 | |
| SCHEMBL12260302 | 0.99 | RXFP1 (0.71) | RXFP1TP53MAPK1KMT2AMEN1 | |
| SCHEMBL12260301 | 0.96 | RXFP1 (0.71) | RXFP1TP53MAPK1KMT2AMEN1 | |
| SCHEMBL17744968 | 0.93 | RXFP1 (0.75) | RXFP1TP53MAPK1KMT2AMEN1 | |
| SCHEMBL5462777 | 0.90 | RXFP1 (0.78) | RXFP1TP53MAPK1KMT2AMEN1 | |
| SCHEMBL19919963 | 0.90 | RXFP1 (0.68) | RXFP1TP53MAPK1KMT2AMEN1 | |
| SCHEMBL12260506 | 0.88 | RXFP1 (0.69) | RXFP1TP53MAPK1KMT2AMEN1 | |
| SCHEMBL12260543 | 0.88 | RXFP1 (0.69) | RXFP1TP53MAPK1KMT2AMEN1 | |
| SCHEMBL12260312 | 0.88 | RXFP1 (0.66) | RXFP1TP53MAPK1KMT2AMEN1 | |
| SCHEMBL12260317 | 0.88 | RXFP1 (0.66) | RXFP1TP53MAPK1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3229811-B1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GRI BIO INC (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3229811-B1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GRI BIO INC (US) | 2021-02-24 | — | — | EP | disclosed |
| WO-2016094226-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GLYCOREGIMMUNE, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | ALTIUM GROWTH FUND, LP | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | RXRA, RXRG, CX3CR1 | RXFP1 219/4885TP53 2836/4885MAPK1 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.